Skip to main content
Premium Trial:

Request an Annual Quote

Peakadilly Changes Name to Pronota in Effort to Shore Up Biomarker Identity

This update corrects the spelling of the new company. It is Pronota, not Pronata.
NEW YORK (GenomeWeb News) — Belgian company Peakadilly has changed its name to Pronota to reflect its emphasis on protein biomarker discovery, the firm said today.
The company also said that a recent €8.5 million ($10.97 million) financing round has enabled it to expand its staff, equipment, and facilities, which it will use to position itself more squarely in the protein biomarker market.
Pronota said its signature biomarker technology, the MASStermind, is used to analyze proteomes from samples such as blood. It also plans to use the technology to develop new diagnostic disease screens and therapeutics.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.